In all RA patients, regardless of drug received, pre-treatment GlycA levels were significantly associated with pre-treatment 2C/3C/4C-DAS28-CRP, but not CDAI (Supplementary Tables S4–S9, available at Rheumatology online). The gene discussed is CRP; the disease is rheumatoid arthritis.